中药行业迎政策利好，益盛药业股价微涨资金波动

Group 1: Industry Overview - The Chinese medicine industry is receiving favorable policies, with the Ministry of Industry and Information Technology and seven other departments issuing the "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)" on February 6, 2026, aiming to promote the approval of innovative traditional Chinese medicine drugs and cultivate leading enterprises by 2030 [1] - This policy is expected to provide long-term support for companies like Yisheng Pharmaceutical (002566) [1] Group 2: Company Actions - Yisheng Pharmaceutical announced on February 4, 2026, that it plans to use no more than 50 million yuan of idle funds to purchase financial products, aiming to improve capital efficiency, and this plan has been approved by the board of directors [1] Group 3: Stock Performance - Over the past seven trading days (February 5 to 11, 2026), Yisheng Pharmaceutical's stock price increased by 1.81%, reaching a high of 8.55 yuan, and closed at 8.45 yuan on February 11, with a slight decline of 0.12% on that day [2] - On February 6, there was a net inflow of 1.7795 million yuan in main funds, but a net outflow was observed on February 11 [2] - The current stock price is above the 20-day moving average of 8.194 yuan, and the MACD indicator maintains a bullish signal [2] Group 4: Institutional Insights - Market attention towards Yisheng Pharmaceutical is generally moderate, with institutional ratings primarily neutral [3] - The stock's price-to-earnings ratio (TTM) is 69.31 times, which is higher than the industry average, indicating relatively weak competitiveness and growth potential within the industry, with the overall valuation being in a reasonable range [3] - The fund holding ratio is low at only 0.63%, reflecting limited institutional participation [3]